Ticker > Company >

Sakar Healthcare share price

Sakar Healthcare Ltd.

  53.25 K   80   11 NSE: SAKAR SECTOR: Pharmaceuticals & Drugs

975.55
-40.35 (-3.97%)
NSE: 06 Nov 03:58 PM

Price Summary

Today's High

₹ 1018.95

Today's Low

₹ 956

52 Week High

₹ 1229.85

52 Week Low

₹ 352.5

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 2170.59 Cr.

Enterprise Value

₹ 2240.87 Cr.

No. of Shares

2.22 Cr.

P/E

50.63

P/B

6.27

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  155.54

CASH

₹ 0.26 Cr.

DEBT

₹ 70.53 Cr.

Promoter Holding

51.7 %

EPS (TTM)

₹  19.27

Sales Growth

41.76%

ROE

10.04 %

ROCE

12.52%

Profit Growth

74.18 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year41.76%
3 Year23.59%
5 Year21.59%

Profit Growth

1 Year74.18%
3 Year33.69%
5 Year23.31%

ROE%

1 Year10.04%
3 Year7.31%
5 Year8.78%

ROCE %

1 Year12.52%
3 Year9.45%
5 Year9.89%

Debt/Equity

0.2173

Price to Cash Flow

44.07

Interest Cover Ratio

5.8121

CFO/PAT (5 Yr. Avg.)

2.01792522353768

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2026 51.70 0.00
Jun 2026 52.52 0.00
Mar 2026 52.86 0.00
Dec 2025 52.86 0.00
Sep 2025 52.86 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 33.6880205567024% for the Past 3 years.
  • The company has shown a good revenue growth of 23.5871771217344% for the Past 3 years.
  • The Company has been maintaining an effective average operating margins of 25.6860276521193% in the last 5 years.
  • Company’s PEG ratio is 0.704922883356122.
  • The company has an efficient Cash Conversion Cycle of 33.475 days.
  • The company has a good cash flow management; CFO/PAT stands at 2.01792522353768.
  • The company has a high promoter holding of 51.7%.

 Limitations

  • Company has a poor ROE of 7.3115% over the past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Net Sales 57.56 70.34 71.1 72.97 87.42
Total Expenditure 46.21 51.75 44.86 51.72 63.07
Operating Profit 11.35 18.59 26.24 21.25 24.35
Other Income 1.22 0.51 0.17 1.54 0.28
Interest 1.53 1.78 2.41 1.67 2
Depreciation 5.68 6.37 5.94 6.54 6.6
Exceptional Items 0 0 0 0 0
Profit Before Tax 5.36 10.95 18.06 14.58 16.02
Tax 0.82 0.7 7.04 4.3 4.71
Profit After Tax 4.54 10.25 11.03 10.29 11.31
Adjusted EPS (Rs) 2.04 4.61 4.96 4.62 5.08

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 128.23 133.36 153.35 177.58 251.74
Total Expenditure 98.81 100.09 114.96 127.88 182.44
Operating Profit 29.41 33.26 38.39 49.7 69.29
Other Income 2.17 4.67 3.18 1.31 2.29
Interest 2.91 5.96 7.62 8.55 8.26
Depreciation 9.67 14.99 18.05 20.88 23.56
Exceptional Items 0 0 0 -0.05 0
Profit Before Tax 19.01 16.99 15.9 21.53 39.76
Tax 3.77 4.23 4.23 4.03 9.27
Net Profit 15.24 12.76 11.67 17.5 30.48
Adjusted EPS (Rs.) 8.9 6.7 5.37 7.97 13.7

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 17.12 19.04 21.75 21.95 22.25
Total Reserves 110.42 154.39 240.67 263.61 302.29
Borrowings 85.01 98.23 54.96 53.59 31.35
Other N/C liabilities 8.53 10.27 12.31 13 15.67
Current liabilities 46.78 54.49 59.06 63.19 109.54
Total Liabilities 267.85 336.42 388.74 415.35 481.09
Assets
Net Block 204.65 266.64 314.29 308.96 326.49
Capital WIP 1.23 6.45 0.32 16.7 3.97
Intangible WIP 0 0 0 0 0
Investments 0.01 0.01 0.01 0.01 0.01
Loans & Advances 11.86 7.33 2.44 0.87 10.1
Other N/C Assets 0 0 0 0 0
Current Assets 50.1 55.99 71.69 88.8 140.53
Total Assets 267.85 336.42 388.74 415.35 481.09
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 19.01 16.88 15.9 21.53 39.76
Adjustment 12.5 20.14 24.9 28.96 30.81
Changes in Assets & Liabilities 4.09 0.6 -13.18 -14.08 -17.29
Tax Paid 0.19 -4.27 -3.15 -2.37 -4.01
Operating Cash Flow 35.79 33.34 24.47 34.03 49.26
Investing Cash Flow -90.4 -74.38 -51.54 -30.71 -28.35
Financing Cash Flow 54.56 41.1 27.44 -3.48 -20.96
Net Cash Flow -0.05 0.06 0.37 -0.16 -0.05

Corporate Actions

Investors Details

PARTICULARS Sep 2025% Dec 2025% Mar 2026% Jun 2026% Sep 2026%
promoters 52.86 52.86 52.86 52.52 51.70
ritaben shah 1.10 1.10 1.10 1.10 1.10
sanjay s shah 44.98 44.98 44.98 44.98 44.98
shah aarsh 6.33 - 6.33 6.33 5.60
shah ayushi 0.45 0.45 0.45 0.11 0.02
shah aarsh - 6.33 - - -
PARTICULARS Sep 2025% Dec 2025% Mar 2026% Jun 2026% Sep 2026%
investors 47.14 47.14 47.14 47.48 48.30
cobra india (mauritius) l... 6.28 6.17 5.89 3.94 3.49
hbm healthcare investment... 6.74 6.74 6.74 6.74 6.74
llp 0.33 0.32 0.14 0.18 0.07
tata capital healthcare f... 10.38 10.38 10.38 10.38 10.38
hi-tech chemicals limited... 2.82 2.45 1.06 - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2024
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY26
Concall Q1FY27
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Sakar Healthcare - Quaterly Results 24 Oct, 12:00 AM Sakar Healthcare - Quaterly Results 25 Jul, 12:00 AM Sakar Healthcare - Quaterly Results 13 May, 12:00 AM Sakar Healthcare - Quaterly Results 6 Feb, 12:00 AM Sakar Healthcare - Quaterly Results 25 Jul, 12:00 PM Sakar Healthcare - Quaterly Results 25 Jul, 12:00 PM Sakar Healthcare - Quaterly Results 25 Jul, 12:00 PM Sakar Healthcare - Quaterly Results 15 May, 12:00 PM Sakar Healthcare - Quaterly Results 15 May, 12:00 PM Sakar Healthcare - Quaterly Results 15 May, 12:00 PM Sakar Healthcare to supply oncology products to Accord Healthcare 24 Feb, 2:11 PM Sakar Healthcare - Quaterly Results 8 Feb, 12:00 PM Sakar Healthcare - Quaterly Results 8 Feb, 12:00 PM Sakar Healthcare - Quaterly Results 8 Feb, 12:00 PM Sakar Healthcare - Quaterly Results 22 Oct, 12:00 PM Sakar Healthcare - Quaterly Results 22 Oct, 12:00 PM Sakar Healthcare - Quaterly Results 22 Oct, 12:00 PM Sakar Healthcare - Quaterly Results 13 Aug, 12:00 PM Sakar Healthcare - Quaterly Results 13 Aug, 12:00 PM Sakar Healthcare - Quaterly Results 21 May, 12:00 PM Sakar Healthcare - Quaterly Results 21 May, 12:00 PM Sakar Healthcare - Quaterly Results 21 May, 12:00 PM Sakar Healthcare - Quaterly Results 10 Feb, 12:00 PM Sakar Healthcare - Quaterly Results 10 Feb, 12:00 PM Sakar Healthcare - Quaterly Results 10 Feb, 12:00 PM Sakar Healthcare - Quaterly Results 6 Nov, 12:00 PM Sakar Healthcare - Quaterly Results 6 Nov, 12:00 PM Sakar Healthcare - Quaterly Results 14 Aug, 12:00 PM Sakar Healthcare - Quaterly Results 14 Aug, 12:00 PM Sakar Healthcare inks pact with Ferring Pharmaceuticals, Bazell Pharma 18 May, 11:00 AM Sakar Healthcare inks pact with Pharmaceutical Oriented Services 11 May, 12:31 PM Sakar Healthcare - Quaterly Results 10 Feb, 12:00 PM Sakar Healthcare - Quaterly Results 10 Feb, 12:00 PM Sakar Healthcare - Quaterly Results 10 Feb, 12:00 PM Sakar Healthcare - Quaterly Results 22 Oct, 12:00 PM Sakar Healthcare - Quaterly Results 22 Oct, 12:00 PM Sakar Healthcare - Quaterly Results 22 Oct, 12:00 PM Sakar Healthcare’s OSD, API blocks get WHO GMP approval from FDCA 12 Oct, 12:58 PM Sakar Healthcare signs agreement with Zydus Life Sciences 7 Oct, 10:10 AM Sakar Healthcare - Quaterly Results 6 Aug, 12:00 PM Sakar Healthcare - Quaterly Results 6 Aug, 12:00 PM Sakar Healthcare - Quaterly Results 6 Aug, 12:00 PM Sakar Healthcare - Quaterly Results 20 May, 12:00 PM Sakar Healthcare - Quaterly Results 20 May, 12:00 PM Sakar Healthcare - Quaterly Results 20 May, 12:00 PM Sakar Healthcare - Quaterly Results 8 Feb, 12:00 PM Sakar Healthcare - Quaterly Results 8 Feb, 12:00 PM Sakar Healthcare - Quaterly Results 8 Feb, 12:00 PM Sakar Healthcare gets EU GMP approval to manufacture, supply products to Europe 7 Oct, 3:55 PM

Sakar Healthcare Stock Price Analysis and Quick Research Report. Is Sakar Healthcare an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Sakar Healthcare. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Sakar Healthcare has a PE ratio of 50.6342582500285 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Sakar Healthcare has ROA of 6.8013% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Sakar Healthcare has a Current ratio of 1.283.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Sakar Healthcare has a ROE of 10.0407%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Sakar Healthcare has a Debt to Equity ratio of 0.2173 which means that the company has low proportion of debt in its capital.

  • Sales growth: Sakar Healthcare has reported revenue growth of 41.7555% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Sakar Healthcare for the current financial year is 27.5263768392284%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Sakar Healthcare is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Sakar Healthcare is Rs 19.2666. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Sakar Healthcare in Ticker for free. Also, one can get the intrinsic value of Sakar Healthcare by using Valuation Calculators, which are available with a Finology ONE subscription. 

Sakar Healthcare FAQs

Q1. What is Sakar Healthcare share price today?
Ans: The current share price of Sakar Healthcare is Rs 975.55.

Q2. What is the market capitalisation of Sakar Healthcare?
Ans: Sakar Healthcare has a market capitalisation of Rs 2170.58997005 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Sakar Healthcare?
Ans: The PE ratio of Sakar Healthcare is 50.6342582500285 and the P/B ratio of Sakar Healthcare is 6.2720039295257, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Sakar Healthcare share?
Ans: The 52-week high share price of Sakar Healthcare is Rs 1229.85, and the 52-week low share price of Sakar Healthcare is Rs 352.5.

Q5. Does Sakar Healthcare pay dividends?
Ans: Currently, Sakar Healthcare does not pay dividends. Dividend yield of Sakar Healthcare is around 0%.

Q6. What are the face value and book value of Sakar Healthcare shares?
Ans: The face value of Sakar Healthcare shares is Rs 10, while the book value per share of Sakar Healthcare is around Rs 155.5404. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Sakar Healthcare?
Ans: Sakar Healthcare has a total debt of Rs 70.5339 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Sakar Healthcare?
Ans: The ROE of Sakar Healthcare is 10.0407% and ROCE of Sakar Healthcare is 12.5205%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Sakar Healthcare a good buy for the long term?
Ans: The Sakar Healthcare long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Sakar Healthcare undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Sakar Healthcare appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Sakar Healthcare’s financials?
Ans: You can review Sakar Healthcare’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Sakar Healthcare
X